T. Rowe Price reports 7.5% BioLife stake
BIOLIFE SOLUTIONS INC (BLFS) is the subject of an amended Schedule 13G filing in which T. Rowe Price Investment Management, Inc. reports beneficial ownership of 3,665,965 shares of BLFS common stock, representing 7.5% of the class, as of August 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BIOLIFE SOLUTIONS INC (BLFS) is the subject of an amended Schedule 13G filing in which T. Rowe Price Investment Management, Inc. reports beneficial ownership of 3,665,965 shares of BLFS common stock, representing 7.5% of the class, as of August 31, 2026.
T. Rowe Price Investment Management, Inc., a Maryland entity, reports sole voting and sole dispositive power over all 3,665,965 shares and no shared voting or dispositive power. The filer states that the filing should not be construed as an admission that it is the beneficial owner of these securities and explicitly denies such beneficial ownership.
Key Figures
Key Terms
beneficial owner regulatory
Sole Voting Power financial
Sole Dispositive Power financial
Percent of class financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in BLFS does T. Rowe Price Investment Management report in this Schedule 13G/A?
What percentage of BioLife Solutions (BLFS) common stock is reported as beneficially owned?
Where is T. Rowe Price Investment Management, Inc. organized and what is its citizenship in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.